Health care situation in patients with allergic respiratory diseases with special focus on specific immunotherapy

Valbert, Frederik; Neusser, Silke; Riederer, Cordula; Wobbe-Ribinski, Stefanie; Klimek, Ludger; Sperl, Annette; Pfaar, Oliver; Werfel, Thomas; Hamelmann, Eckard; Neumann, Anja; Wasem, Jürgen; Biermann‐Stallwitz, Janine

doi:10.1007/s40629-020-00149-z

Cited by 3 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A large proportion of individuals with AIT within the routine data period were intentionally recruited for questions regarding the care situation (published elsewhere) [ 19 , 45 ]. The resulting AIT rate in the VerSITA study of 54% within the routine data period is far above the amount that is estimated for Germany and leads to an overestimation of the average costs for AIT medication.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Quality of life and healthcare costs of patients with allergic respiratory diseases: a cross-sectional study

et al. 2023

Self Cite

View full text Add to dashboard Cite

Background Allergic rhinitis (AR) and allergic asthma (AA) are chronic respiratory diseases that represent a global health problem. One aim of this study was to analyze the Health-related Quality of Life (HRQoL) of the patients in order to identify statistically significant influencing factors that determine HRQoL. Another aim was to assess and analyze data on cost-of-illness from a statutory health insurance perspective. Methods The EQ-5D-5L was used to evaluate the patients’ HRQoL. To identify the factors influencing the HRQoL, a multinomial logistic regression analysis was conducted using groups based on the EQ-5D-5L index value as dependent variable. Routine data were analyzed to determine total healthcare costs. Results The average EQ-5D-5L index was 0.85 (SD 0.20). A high age, the amount of disease costs, low internal health-related control beliefs and high ozone exposure in the residential area were found to be statistically significant influencing factors for a low HRQoL, whereas low age, male sex and a good possibility to avoid the allergens were found to be statistically significant factors influencing a high HRQoL. On average, the study participants incurred annual costs of €3072 (SD: 3485), of which €699 (SD: 743) could be assigned to allergic respiratory diseases. Conclusions Overall, the patients in the VerSITA study showed a high level of HRQoL. The identified influencing factors can be used as starting points for improving the HRQoL of patients with allergic respiratory diseases. From the perspective of a statutory health insurance, per person expenditures for allergic respiratory diseases are rather low.

show abstract

Section: Discussionmentioning

confidence: 99%

“…For the analyses routine data and survey data were merged. Further information on how the study was conducted, how participants were selected and a description of the VerSITA questionnaire can be found elsewhere [ 19 ].…”

Section: Methodsmentioning

confidence: 99%

Quality of life and healthcare costs of patients with allergic respiratory diseases: a cross-sectional study

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…A more detailed description of the study protocol including a figure showing the principal flow of the study is published elsewhere 17 …”

Section: Methodsmentioning

confidence: 99%

Care with allergen immunotherapy for allergic respiratory diseases in Germany—Predictors and deficits

Valbert

Neusser

Pfaar

et al. 2022

Clin Experimental Allergy

Self Cite

View full text Add to dashboard Cite

Background: Allergen immunotherapy (AIT) represents the only possibility of causal therapy for allergic respiratory diseases. Although the prevailing high prevalence of allergic diseases and restrictions in the daily lives of patients, AIT is offered to a suboptimal number of patients in Germany.Methods: Insured patients with documented allergic respiratory disease of one of the largest statutory health insurances in Germany, 'DAK-Gesundheit', were contacted by postal mail and asked to participate in the study. In case of written consent, primary and secondary data of patients were collected and analysed. Patient characteristics, predictors of being offered AIT, predictors of performing AIT and guideline-compliant care were analysed.Results: 2505 subjects were included in the VerSITA study. Allergy to tree pollen and native speaking were identified as predictors, which increase the probability of being offered AIT. The probability was significantly decreased by the characteristics allergic rhinitis only, allergic asthma only, age in years, non-German citizenship, no graduation and lower secondary qualification. Significant positive predictors for an AIT to be actually performed were: Allergy to tree pollen and male sex. Predictors that decrease the likelihood that AIT is performed were: only allergic asthma, current smoker, former smoker, age and non-German citizenship. Furthermore, it was possible to identify characteristics in which guideline-compliant patients differed significantly from the rest of the study population. Conclusions:Based on statutory health insurance data and patient survey data, the VerSITA study provides a broad and in-depth overview of the care situation with regard to AIT in Germany and identifies deficits.

show abstract

The pharmacotherapeutic management of allergic rhinitis in people with asthma

Klimek,

Werminghaus,

Casper

et al. 2024

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

Health care situation in patients with allergic respiratory diseases with special focus on specific immunotherapy

Cited by 3 publications

References 6 publications

Quality of life and healthcare costs of patients with allergic respiratory diseases: a cross-sectional study

Quality of life and healthcare costs of patients with allergic respiratory diseases: a cross-sectional study

Care with allergen immunotherapy for allergic respiratory diseases in Germany—Predictors and deficits

The pharmacotherapeutic management of allergic rhinitis in people with asthma

Contact Info

Product

Resources

About